1. Fetal Tuberous Sclerosis: Sirolimus for the Treatment of Fetal rhabdomyoma
- Author
-
Mónica Rebelo, Sofia Jorge, Ana Dagge, Luísa Pinto, Luísa Andrade Silva, and Estela Nogueira
- Subjects
Pediatrics ,medicine.medical_specialty ,Rhabdomyoma ,Pathology and Forensic Medicine ,Heart Neoplasms ,Tuberous sclerosis ,Fetus ,Fetal rhabdomyoma ,Pregnancy ,Tuberous Sclerosis ,medicine ,Humans ,Child ,Vitamin A ,Sirolimus ,Tumor size ,business.industry ,Arrhythmias, Cardiac ,General Medicine ,medicine.disease ,Carotenoids ,Prenatal treatment ,Pediatrics, Perinatology and Child Health ,Gestation ,Female ,business ,medicine.drug - Abstract
Background Sirolimus constitutes a safe and effective treatment for cardiac manifestations of tuberous sclerosis complex (TSC) in children but only four cases describing prenatal treatment of rhabdomyomas with mTOR inhibitors have been published. Case In this case, sirolimus was initiated at 26 weeks´ gestation in a pregnant woman with TSC with a fetus with a large rabdomyoma conditioning severe arrythmia. There was a significant reduction in the tumor size with ongoing treatment and a partial reversion of the arrythmia. Conclusion m-TOR inhibitors can be considered for severe cases of fetal rhabdomyomas with poor prognosis given its potencial benefits.
- Published
- 2021